Edition:
United States

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.76EUR
25 May 2018
Change (% chg)

-- (--)
Prev Close
€1.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
680,386
52-wk High
€1.79
52-wk Low
€0.75

Chart for

About

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the... (more)

Overall

Beta: -0.26
Market Cap(Mil.): €522.26
Shares Outstanding(Mil.): 296.07
Dividend: --
Yield (%): --

Financials

  G9U.BR Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -0.28 -- --
ROI: -105.02 -7.54 13.04
ROE: -148.10 -10.33 14.90

BRIEF-Takeda Says Announces Voluntary And Conditional Public Takeover Bid For Outstanding Shares,Warrants And American Depositary Shares Of Tigenix NV To Commence April 30, 2018

* SAYS ANNOUNCES VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID FOR OUTSTANDING SHARES, WARRANTS AND AMERICAN DEPOSITARY SHARES OF TIGENIX NV TO COMMENCE APRIL 30, 2018 Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

Apr 25 2018

BRIEF-Tigenix FY Operating Loss Widens to 53.2 Million Euros

* FY OPERATING LOSS OF EUR 53.2 MILLION VERSUS LOSS OF EUR 3.0 MILLION YEAR AGO

Apr 12 2018

BRIEF-Tigenix And Takeda Announce Alofisel® (Darvadstrocel) Receives Approval To Treat Complex Perianal Fistulas In Crohn's Disease In Europe

* TIGENIX AND TAKEDA ANNOUNCE ALOFISEL® (DARVADSTROCEL) RECEIVES APPROVAL TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE IN EUROPE

Mar 23 2018

BRIEF-Tigenix Says Received Transparency Notification From Jpmorgan Chase & Co​ On Jan 16

* ‍TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007​‍

Jan 18 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion (8.12 billion pounds) burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

Jan 08 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

Jan 08 2018

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

Jan 05 2018

BRIEF-Tigenix Confirms Strategic Focus On Cx601 And Its Adipose Derived Stem Cell Platform

* CONFIRMS STRATEGIC FOCUS ON CX601 AND ITS ADIPOSE DERIVED STEM CELL (EASC) PLATFORM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 20 2017

BRIEF-Tigenix Plans To Focus On Its eASC Platform And Product Candidates Cx601 And Cx611

* TIGENIX NV SAYS PLANS TO FOCUS ITS RESOURCES AND CAPABILITIES ON ITS EASC PLATFORM TECHNOLOGY AND ITS PRODUCT CANDIDATES CX601 AND CX611 Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

Dec 15 2017

Earnings vs. Estimates